On September 9, 2026, Encoded Therapeutics Inc. announced the closing of a $275 million Series F financing. The round was co-led by GV and another healthcare fund, with participation from ARCH Venture Partners, Braidwell LP, Farallon Capital Management, Illumina Ventures, Invus, Janus Henderson Investors, Matrix Capital Management, Nolan Capital, RTW Investments, SoftBank Vision Fund 2, and Venrock.

The proceeds will support the pivotal study of ETX101, an AAV9-based gene therapy for infants and young children with SCN1A+ Dravet syndrome, as well as an expansion study in children and adolescents up to 18 years of age. The funding will also support the commercial scale-up of internal GMP manufacturing capabilities and pipeline advancement, including ETX301, an AAV9-based vectorized microRNA gene therapy for the treatment of post-amputation neuroma pain, toward an IND submission in 2027.

The continued investment in AAV gene therapy programs reflects growing confidence in the potential of this field. As promising candidates advance, robust CMC strategies and scalable manufacturing capabilities will be critical to demonstrating development readiness and supporting the long-term value of these programs.

As part of the broader gene therapy ecosystem, Genevoyager provides end-to-end CRO/CDMO services, from drug discovery to large-scale manufacturing, leveraging both HEK293 and our proprietary Bac/Sf9 AAV production platforms to produce high-quality AAV vectors with minimal impurities and no detectable rcAAV. With 30+ drug development projects and multiple IIT/IND submissions supported, Genevoyager has helped advance AAV-based gene therapies and recombinant protein vaccines into clinical development, including programs targeting Parkinson’s disease, refractory epilepsy, hepatitis B, and cancer, with selected programs receiving FDA IND clearance and entering Phase I trials. Backed by extensive experience, we are committed to delivering safe, high-quality solutions to academic, pharmaceutical, and biotech partners worldwide.

Source:

https://encoded.com/encoded-therapeutics-raises-275-million-in-series-f-financing-to-advance-etx101-through-pivotal-development-and-accelerate-its-precision-genetic-medicines-neurology-pipeline/?_gl=1*w5ggmx*_up*MQ..*_ga*MTQ5MjY4NzYxNS4xNzg5MDExMjg2*_ga_HYVB8PCGTG*czE3ODkwMTEyODMkbzEkZzEkdDE3ODkwMTEzMDckajM2JGwwJGgw

Image source:

https://encoded.com/our-science/?_gl=1*1q5sjzt*_up*MQ..*_ga*MTQ5MjY4NzYxNS4xNzg5MDExMjg2*_ga_HYVB8PCGTG*czE3ODkwMTEyODMkbzEkZzEkdDE3ODkwMTEzMTgkajI1JGwwJGgw

Note: